Literature DB >> 8548776

Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs.

I Royer1, B Monsarrat, M Sonnier, M Wright, T Cresteil.   

Abstract

The metabolism of docetaxel by human liver microsomes was investigated in vitro and compared with that of paclitaxel. A main docetaxel metabolite was generated by human liver microsomes in the presence of NADPH: retention time in high pressure liquid chromatography and its ion fragmentation in mass spectrometry were identical to those of the authentic derivative hydroxylated at the butyl group of the C13 side chain. Kinetic measurements and chemical and immunological inhibitions demonstrated that CYP3A was implicated in the hydroxylation of docetaxel: Km (2 microM) and Vm values of docetaxel for human liver microsomes were comparable to those calculated for the formation of metabolite p-hydroxy-phenyl C3' paclitaxel (M4). Docetaxel hydroxylation correlated only with the CYP3A content of microsomes and with CYP3A-dependent 6 beta-hydroxylation of testosterone and 16-hydroxylation of dehydroepiandrosterone. The formation of hydroxydocetaxel was strongly reduced by CYP3A inhibitors such as ketoconazole, midazolam, erythromycin, testosterone, orphenadrine, and troleandomycin, whereas quinidine (CYP2D6), hexobarbital, tolbutamide, and mephenytoin (CYP2C) had no or little effect. The hydroxylation of docetaxel exhibited a highly positive correlation with the formation of metabolite M4 of paclitaxel (r = 0.929, P < 0.0001, n = 12), but not with its 6-hydroxylation (r = 0.48, P > 0.15). Docetaxel abolished the hydroxylation of paclitaxel metabolite M4, but was totally inactive on its 6 alpha-hydroxylation. Conversely, paclitaxel reduced significantly the hydroxylation of docetaxel. We examined in vitro the possible interaction among docetaxel, paclitaxel, and drugs which could be associated during chemotherapy. Cisplatin, verapamil, doxorubicin, vinblastine, and vincristine at concentrations usually recommended did not markedly modify taxoid metabolism. Ranitidine and diphenylhydramine had no effect, but 100 microM cimetidine partially inhibited the formation of 6 alpha-hydroxypaclitaxel. Pretreatment of patients with barbiturates strikingly stimulated docetaxel hydroxylation, whereas no acceleration of docetaxel hydroxylation was noticed in a patient receiving steroids.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8548776

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

Review 1.  Nanoways to overcome docetaxel resistance in prostate cancer.

Authors:  Aditya Ganju; Murali M Yallapu; Sheema Khan; Stephen W Behrman; Subhash C Chauhan; Meena Jaggi
Journal:  Drug Resist Updat       Date:  2014-04-05       Impact factor: 18.500

2.  Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA.

Authors:  Sandra M Swain; Young-Hyuck Im; Seock-Ah Im; Valorie Chan; David Miles; Adam Knott; Emma Clark; Graham Ross; José Baselga
Journal:  Oncologist       Date:  2014-05-28

Review 3.  Interactions between antiretrovirals and antineoplastic drug therapy.

Authors:  Tony Antoniou; Alice L Tseng
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of docetaxel.

Authors:  S J Clarke; L P Rivory
Journal:  Clin Pharmacokinet       Date:  1999-02       Impact factor: 6.447

Review 5.  Drug interactions of paclitaxel and docetaxel and their relevance for the design of combination therapy.

Authors:  L Vigano; A Locatelli; G Grasselli; L Gianni
Journal:  Invest New Drugs       Date:  2001-05       Impact factor: 3.850

6.  Human liver microsomal metabolism of paclitaxel and drug interactions.

Authors:  P B Desai; J Z Duan; Y W Zhu; S Kouzi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Jul-Sep       Impact factor: 2.441

7.  Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study.

Authors:  Saroj Niraula; Greg Pond; Ronald de Wit; Mario Eisenberger; Ian F Tannock; Anthony M Joshua
Journal:  Can Urol Assoc J       Date:  2013 Jan-Feb       Impact factor: 1.862

8.  Stearoyl gemcitabine nanoparticles overcome obesity-induced cancer cell resistance to gemcitabine in a mouse postmenopausal breast cancer model.

Authors:  Rebecca E De Angel; Jorge M Blando; Matthew G Hogan; Michael A Sandoval; Dharmika S P Lansakara-P; Sarah M Dunlap; Stephen D Hursting; Zhengrong Cui
Journal:  Cancer Biol Ther       Date:  2013-01-28       Impact factor: 4.742

Review 9.  Practical treatment guide for dose individualisation in cancer chemotherapy.

Authors:  P Canal; E Chatelut; S Guichard
Journal:  Drugs       Date:  1998-12       Impact factor: 9.546

10.  Preclinical studies of YK-4-272, an inhibitor of class II histone deacetylases by disruption of nucleocytoplasmic shuttling.

Authors:  Hye-Sik Kong; Shuo Tian; Yali Kong; Guanhua Du; Li Zhang; Mira Jung; Anatoly Dritschilo; Milton L Brown
Journal:  Pharm Res       Date:  2012-07-27       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.